MORRISTOWN, N.J., March 25, 2011 /PRNewswire/ — Watson
Pharmaceuticals, Inc. (NYSE:
WPI), today confirmed that the United States District Court for
the District of Delaware has ruled that Watson’s generic version of
Fentora® (fentanyl buccal tablets C-II) infringes United States
Patent No. 6,264,981 (the ‘981 Patent). The Company said that
it was reviewing the court’s decision and would evaluate all
available options, including an appeal.
Watson’s Abbreviated New Drug Application (“ANDA”) for its
generic version of Fentora® has been approved by the FDA.
In 2008, Cephalon sued Watson for patent infringement related to
its generic version of Fentora®. On March 11, 2011, the
United States District Court for the District of Delaware ruled
that Watson’s product does not infringe United States Patent Nos.
6,200,604 and 6,974,590 (the ‘604 and ‘590 Patents) and that the
‘604 and ‘590 Patents are invalid.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is a leading integrated global
specialty pharmaceutical company. The Company is engaged in
the development and distribution of generic pharmaceuticals and
specialized branded pharmaceutical products focused on Urology and
Women’s Health. Watson has operations in many of the world’s
established and growing international markets.
For press release and other company information, visit Watson
Pharmaceuticals’ Web site at http://www.watson.com.
Statements contained in this press release that refer to
non-historical facts are forward-looking statements that reflect
Watson’s current perspective of existing information as of the date
of this release. It is important to note that Watson’s goals
and expectations are not predictions of actual performance.